TNFRSF18 and autoimmune disease: Consistent with the co-activating effect of agonist mAbs on conventional T cells, which results in increased anti-tumor effects and infection resistance, the decrease in inflammatory and autoimmune diseases in GITR−/− mice also indicates a possible therapeutic effect of GITR antagonism.